Abstract: Inhibitors of mammalian target of rapamycin (mTOR) have been widely applied both as anti-rejection medicine after transplant surgery and anti-tumor agent in various cancer patients． However, it is found to have inflammation-related adverse effect in clinical practice, such as glomerulonephritis, interstitial pneumonia, chronic inflammatory anemia and so on． Cytokine is an important component of inflammatory mediators, whose secretion will be affected by mTOR inhibitors． This article reviews the effect of mTOR inhibitors on the secretion of inflammation-related cytokines and the possible mechanisms, in order to provide some tips for improving the inflammation-related adverse effect induced by mTOR inhibitors．